Replimune Group REPL Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Replimune Group in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Replimune Group's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Replimune Group's common stock, shares authorized (in shares)?
- Replimune Group (REPL) reported common stock, shares authorized (in shares) of $150M in Q4 2025.
- How has Replimune Group's common stock, shares authorized (in shares) changed year-over-year?
- Replimune Group's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $150M to $150M.
- What is the long-term trend for Replimune Group's common stock, shares authorized (in shares)?
- Over 4 years (2021 to 2025), Replimune Group's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $150M to $150M.